Hansa Biopharma 2022 Healthcare Conference Investor Presentation

Hansa Biopharma presents its clinical-stage immunology pipeline and recently approved Idefirix for kidney transplantation in Europe. The company highlights its validated technology platform, expanded organization of 145 employees, and strong cash position through 2024, with applications across transplantation and autoimmune diseases.